Latest Strategy Changes News

Culpeo Minerals Limited reported a net cash outflow of $246,000 for the December 2024 quarter but retains robust liquidity with $3.7 million in available funding. The company’s cash position and financing facilities suggest it is well-positioned to continue its exploration activities.

Pursuit Minerals has reported a remarkable 339% increase in lithium resources at its Rio Grande Sur project in Argentina, alongside plans to commence lithium carbonate production by Q1 2025. The company is also actively pursuing acquisitions and reviewing its gold assets amid tight cost controls.

Revolver Resources reports encouraging leach test results at its Dianne Copper Mine, moving closer to production in H2 2025, while securing new funding through a royalty agreement to support development and exploration.

Ovanti Limited has made significant strides in its plan to enter the US Buy Now Pay Later market, delivering a comprehensive strategic report and strengthening its executive team to support expansion.

Nutritional Growth Solutions reported a slight revenue decline in Q4 FY24 but remains optimistic about growth and profitability in FY25, buoyed by renewed Walmart partnerships and expanding Asian distribution.

HALO Technologies reports a robust 45.5% increase in operating revenue for 2024, driven by surging Funds Under Management and brokerage income, while advancing its UK market entry alongside a $6.75 million capital raise.

Magnis Energy Technologies reports ongoing progress on its Nachu Graphite Project while grappling with Imperium3’s bankruptcy and a prolonged ASX trading suspension.

Peppermint Innovation Ltd has bolstered its financial position with a $3 million convertible note while navigating a challenging quarter marked by cybersecurity disruptions and strategic divestments. The company is poised for recovery with new advisory expertise and enhanced payment integrations in the Philippines.

Purifloh Limited has made significant progress in its PFAS destruction technology, securing a $100,000 BRII feasibility grant while navigating challenges to resume trading on the ASX.

Paradigm Biopharmaceuticals has launched a Loyalty and Piggyback Options program aimed at rewarding shareholders and raising up to $111.96 million to support its pivotal Phase III clinical trial.

Jindalee Lithium Limited reported a $935,000 net cash outflow for the December 2024 quarter, maintaining a cautious but confident stance on securing future funding to support ongoing exploration activities.

Jindalee Lithium’s latest quarterly report confirms a 63-year life for its McDermitt Lithium Project, underpinned by robust financial metrics and a maiden ore reserve that taps just a fraction of its vast resource.